logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

EHA 2019 – Durable benefits with brentuximab vedotin plus chemotherapy as frontline treatment in classical Hodgkin lymphoma

According to the 3-year update of ECHELON-1 trial, A+AVD compares favourably with ABVD in patients with stage III/IV disease, independently of PET2 status